FDA approves Impax’s RYTARY to treat Parkinson’s disease
RYTARY is an extended-release oral capsule formulation of carbidopa-levodopa. It is not indicated for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. The drug contains immediate